ClinicalTrials.gg

Program

toripalimab

Also written as “Toripalimab”, “Toripalimab Injection” and “CM082 plus JS001”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma · Stomach Neoplasms · Carcinoma, Transitional Cell, led by 5 companies.

Furthest: phase 4, since Mar 17, 202213 company-led studies, 10 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen54 open or runningphase 2since Mar 17, 2022Mar 17, 2022none ahead
Mabwell (Shanghai) Bioscience33 open or runningphase 3since Sep 9, 2024Sep 25, 2023Dec 31, 2026phase 2 · NCT06079112
Coherus Oncology22 open or runningphase 4since Jun 10, 2024Jun 10, 2024Dec 2027phase 4 · NCT06457503
Suzhou Zelgen Biopharmaceuticals21 open or runningphase 2since Aug 3, 2020Aug 3, 2020none ahead
CSPC Pharmaceutical Group10 open or runningphase 3since Dec 12, 2018Dec 12, 2018none ahead

Also a collaborator on its studies: medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2018First study: phase 3 study in Triple Negative Breast NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03777579 · 375 enrolled · China
  2. Aug 3, 2020Suzhou Zelgen Biopharmaceuticals's first study: phase 2 study in Advanced Hepatocellular CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT04503902 · 46 enrolled · China
  3. Oct 21, 2020Phase 1 study in Unresectable Hepatocellular CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT04605185 · 18 enrolled · China
  4. Mar 17, 2022RemeGen's first study: phase 2 study in Muscle Invasive Bladder CarcinomaNew to RemeGenRemeGen · NCT05297552 · 40 planned · China
  5. Sep 1, 2023Phase 2 study in Advanced Solid TumorRemeGen · NCT06038396 · 48 planned · China
  6. Sep 25, 2023Mabwell (Shanghai) Bioscience's first study: phase 2 study in Advanced Urothelial CarcinomaNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT06079112 · 100 planned · China
  7. Oct 23, 2023Phase 2 study in Breast NeoplasmsRemeGen · NCT06105008 · China
  8. Nov 23, 2023Phase 2 study in Stomach NeoplasmsRemeGen · NCT06155383 · 90 planned · China
  9. Jan 17, 2024Phase 2 study in Breast NeoplasmsRemeGen · NCT06227117 · 120 planned · China
  10. Jun 10, 2024Coherus Oncology's first study: phase 4 study in Nasopharyngeal NeoplasmsNew to Coherus OncologyCoherus Oncology · NCT06457503 · 100 planned · United States, Canada
  11. Sep 9, 2024Phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326 · 460 planned · China
  12. Oct 23, 2024Phase 1 study in Neoplasm MetastasisCoherus Oncology · NCT06657144 · 154 planned · United States, Taiwan
  13. Jan 13, 2025Phase 2 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06823427 · 60 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112
  2. Sep 2027Primary completion: phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326
  3. Dec 2027Primary completion: phase 4 study in Nasopharyngeal NeoplasmsCoherus Oncology · NCT06457503
  4. Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisCoherus Oncology · NCT06657144

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06823427Carcinoma, Transitional Cell · China2RecruitingMabwell (Shanghai) BioscienceJun 202660
NCT06657144Neoplasm Metastasis · United States, Taiwan1RecruitingCoherus OncologyJan 2028154
NCT06592326Carcinoma, Transitional Cell · China3RecruitingMabwell (Shanghai) BioscienceSep 2027460
NCT06457503Nasopharyngeal Neoplasms · United States, Canada4RecruitingCoherus OncologyDec 2027100
NCT06227117Breast Neoplasms · China2RecruitingRemeGenDec 2025120
NCT06155383Stomach Neoplasms · China2RecruitingRemeGenJan 31, 202590
NCT06105008Breast Neoplasms · China2WithdrawnRemeGenDec 20, 20250
NCT06079112Advanced Urothelial Carcinoma · China2RecruitingMabwell (Shanghai) BioscienceDec 31, 2026100
NCT06038396Advanced Solid Tumor · China2RecruitingRemeGenFeb 28, 202648
NCT05297552Muscle Invasive Bladder Carcinoma · China2RecruitingRemeGenJun 1, 202440
NCT04605185Unresectable Hepatocellular Carcinoma · China1Active, not recruitingSuzhou Zelgen BiopharmaceuticalsDec 202418
NCT04503902Advanced Hepatocellular Carcinoma · China2UNKNOWNSuzhou Zelgen BiopharmaceuticalsDec 202346
NCT03777579Triple Negative Breast Neoplasms · China3SuspendedCSPC Pharmaceutical GroupDec 30, 2019375

How it is read

Names in the registry

  • “Toripalimab”, 14 entries
  • “Toripalimab Injection”, 3 entries
  • “CM082 plus JS001”, 3 entries
  • “ABO2109 Injection;Toripalimab”, 2 entries
  • “JS001”, 2 entries

Codes read as this program: JS001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.